1.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: D7913L00077, NCT01579630
|
|
2.
|
Phase: Phase III Type: Prevention, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: KROG-4-2008-0276, 4-2008-0276, NCT00955695
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ZhejiangCH06, NCT01158170
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OXFORD-COG, COG, UO-COG, EUDRACT-2007-005391-13, ISRCTN-29580179, AZ-D7913L00059, EU-21085, NCT01243398
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: C-TONG 1104, NCT01405079
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791LC00001, NCT01544179
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: NS 01/03/08, 2008/00196, NCT00809237
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NCCCTS-09-433, NCT01027676
|
|
9.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GECP10-03, 2010-024178-21, NCT01513174
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000415879, MCC-13922, ZENECA-IRUSIRES0256, MCC-IRB-102794, NCT00104728
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000582623, YONSEI-4-2006-0136, ZENECA-YONSEI-4-2006-0136, 4-2006-0136, NCT00616499
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: C-TONG0806, NCT00891579
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CIH-CAMS-CHL-020, CHL-020, NCT01024712
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: not specified Sponsor: Other Protocol IDs: C-TONG0901, NCT01024413
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: Iressa combined with Pem/Cis, NCT01192243
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AMC 2009-0677, NCT01196234
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 70 to 85 Sponsor: Other Protocol IDs: ZhejiangCH10, NCT01291823
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CRUK-UCL-10/0035, UCL/10/0035 v1.0, DORIC, ZENECA-ISSRECE00002, EUDRACT-2010-021531-13, CRUKE/10/044, NCT01310855
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-07-252, NCT01312337
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CS-S10-09, NCT01391260
|
|
21.
|
Phase: Phase II Type: Diagnostic, Tissue collection/Repository, Treatment Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: P01425, 2010-023355-29, 11/H0304/8, NCT01405846
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.123, 2011-001814-33, NCT01466660
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14034, H3E-CR-JMIT(a), NCT01469000
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: SVH-1, NCT01485809
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: 4-2011-0662, NCT01498562
|